Piperazine adipate
(Synonyms: 己二酸哌嗪) 目录号 : GC30962An Analytical Reference Standard
Cas No.:142-88-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Piperazine is an analytical reference standard categorized as a piperazine. This product is intended for research and forensic applications.
Cas No. | 142-88-1 | SDF | |
别名 | 己二酸哌嗪 | ||
Canonical SMILES | O=C(O)CCCCC(O)=O.N1CCNCC1 | ||
分子式 | C10H20N2O4 | 分子量 | 232.28 |
溶解度 | Water : 30 mg/mL (129.15 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.3051 mL | 21.5257 mL | 43.0515 mL |
5 mM | 0.861 mL | 4.3051 mL | 8.6103 mL |
10 mM | 0.4305 mL | 2.1526 mL | 4.3051 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Effect of parbendazole and piperazine adipate on the activity of some enzymes of Ascaridia galli and Heterakis gallinae
Adult Ascaridia galli and Heterakis gallinae obtained from the fowl (Gallus gallus) were treated in vitro with 10(-2) to 10(-5) M parbendazole and piperazine adipate for 10-60 min at 38 degrees C. Both the compounds at 10(-2) M caused mortality of A. galli and H. gallinae after a maximum of 30 min exposure. The effect of the drugs on the homogenates of the treated worm was investigated. Parbendazole (10(-2) M) inhibited malate oxidation by 68% in A. galli and 62% in H. gallinae. Piperazine adipate (10(-2) M) inhibited malate oxidation by 78% in both parasites. In A. galli oxaloacetate reduction was inhibited by 41 and 26% by 10(-2) M parbendazole and piperazine adipate, respectively; with H. gallinae this inhibition was found to be 39 and 55%, respectively. Aldolase activity in both the parasites was also inhibited by 10(-2) M parbendazole and piperazine adipate. Both compounds caused an inhibition of acid phosphomonoesterase activity, but the activities of lactate dehydrogenase and alkaline phosphomonoesterase were not affected significantly. Parbendazole (10(-2) M) had no significant effect on the cholinesterase activity of these parasites, but piperazine adipate (10(-2) M) caused an inhibition of 96% in A. galli and 93% in H. gallinae. The possible mode of action of the drugs is discussed.
Piperazine adipate: a new anthelmintic agent. II. Toxicological and pharmacological studies
Mass therapy with piperazine adipate in the control of threadworm infestations
Treatment of ascariasis in children with piperazine adipate
Pyrantel embonate in mass treatment of ascariasis and comparison with piperazine adipate and santonin-kainic acid complex
A single dose (2.0, 5.0, 10.0 mg/kg) of pyrantel embonate given to three groups consisting 301 children with Ascaris lumbricoides infection achieved a cure rate of 91.3%, 94.4% and 98.9% respectively. Whereas in the other two groups of 71 and 75 patients who received 75 mg/kg body weight with piperazine adipate 2 or 3 consecutive days, the cure rates were 62.0% and 74.7% respectively. Administration of a single recommended dose of santonin-kainic acid complex given to 77 patients achived a cure rate of 80.5% with 91.0% of egg reduction rate. The cure rate resulting from a single lowest dose 2.5 mg/kg pyrantel embonate was significantly higher than those of piperazine adipate and santonin-kainic acid complex in the mass treatment for ascariasis. in addition to the group of 2.5 mg/kg pyrantel embonate treatment, the side effect was lesser than those of the other groups. Considering the efficacy and safety of pyrantel embonate against Ascaris lumbricoides, it would be one of the useful agents for the mass treatment of Ascaris control.